Business Context and Reporting Period
Park Ha Biological Technology Co., Ltd., a Cayman Islands-incorporated foreign private issuer listed on the Nasdaq Capital Market, filed this Form 6-K on June 4, 2026. The report covers the month of June 2026 and discloses the Company's election to rely on the home country practice exemption under Nasdaq Listing Rule 5615(a)(3).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance practices and does not contain financial statements or performance data.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The document solely addresses the Company's adherence to specific corporate governance exemptions relative to Nasdaq standards.
Guidance, Outlook, and Risks
The Company has elected to follow Cayman Islands corporate governance practices in lieu of specific Nasdaq requirements. The exempted rules include:
- Requirement for a majority of independent directors (Rule 5605(b)(1)).
- Requirement to distribute annual and interim reports (Rule 5250(d)).
- Shareholder approval requirements for securities issuance in connection with acquisitions, change of control, equity-based compensation, and significant private placements (Rule 5635).
- Restrictions on disparately reducing or restricting voting rights of existing shareholders (Rule 5640).
The Company's Cayman Islands counsel, Ogier, has certified that these practices are permissible under Cayman Islands law and the Company's memorandum and articles of association. Except for these exemptions, the Company states there are no significant differences in its governance practices from U.S. domestic companies.
Key Facts for Investor Verification
- The Company is exempt from the Nasdaq requirement to have a majority of independent directors on its board.
- Shareholders may not receive annual or interim reports distributed directly by the Company as required by standard Nasdaq rules.
- Shareholder approval may not be required for certain equity issuances, including those related to acquisitions, change of control, or executive compensation.
- The Company's voting rights structure may differ from standard U.S. practices regarding the reduction or restriction of existing shareholder rights.